Ekso Bionics Holdings (EKSO) Receiving Somewhat Positive Press Coverage, Report Finds
News coverage about Ekso Bionics Holdings (NASDAQ:EKSO) has been trending somewhat positive on Thursday, according to Accern. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ekso Bionics Holdings earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.8130303736683 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the headlines that may have effected Accern Sentiment’s rankings:
- Global Hospital and Pharmacy Robots Market 2017-2022- Analysis and Trends (medgadget.com)
- BRIEF-Ekso Bionics raises $34 mln in fully-financed rights offering (reuters.com)
- Ekso Bionics® Raises $34 Million in Fully-Financed Rights Offering (finance.yahoo.com)
- Ekso Bionics Holdings, Inc. (EKSO) Upgraded to Buy at Zacks Investment Research (americanbankingnews.com)
- Is It The Right Time To Buy Ekso Bionics Holdings Inc (EKSO)? (finance.yahoo.com)
Ekso Bionics Holdings (NASDAQ:EKSO) traded down 1.71% during mid-day trading on Thursday, hitting $1.15. 1,344,570 shares of the stock traded hands. The company has a 50 day moving average of $1.55 and a 200-day moving average of $2.28. Ekso Bionics Holdings has a 12-month low of $0.99 and a 12-month high of $6.38. The stock’s market cap is $29.66 million.
Several analysts have recently commented on EKSO shares. Zacks Investment Research raised shares of Ekso Bionics Holdings from a “hold” rating to a “buy” rating and set a $1.50 price objective on the stock in a report on Friday, September 1st. B. Riley reaffirmed a “buy” rating and issued a $4.00 price objective on shares of Ekso Bionics Holdings in a report on Wednesday, May 10th.
ILLEGAL ACTIVITY WARNING: This story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.thecerbatgem.com/2017/09/07/ekso-bionics-holdings-ekso-receiving-somewhat-positive-press-coverage-report-finds.html.
In other news, insider Russ Angold sold 28,254 shares of Ekso Bionics Holdings stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $1.53, for a total value of $43,228.62. Following the transaction, the insider now directly owns 250,678 shares of the company’s stock, valued at approximately $383,537.34. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 259,352 shares of company stock worth $399,373 over the last ninety days. Corporate insiders own 7.10% of the company’s stock.
Ekso Bionics Holdings Company Profile
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
Receive News & Stock Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related stocks with our FREE daily email newsletter.